Conference Report Although opioids are currently dominating the headlines, stimulant drugs like cocaine and methamphetamine never went away. In fact, more Americans use illegal stimulant drugs than all opioids combined… Read More
Browse Our Resources
Recent research on opioid use in states with medical marijuana laws suggests that legal access to marijuana can lead to a decrease in prescription opioid use, as well as reductions in opioid-related harms, including… Read More
DPA Podcast Episode 14: Derek Riffs on How Kellyanne Conway Inadvertently Made the Case for Legalizing Drugs
Kellyanne Conway's lack of experience and inability to effectively address the overdose crisis was on full display last month when she jokingly told a forum of young people: “eat the ice cream, have the… Read More
Rates of opioid use, dependence, and overdose in the United States are reaching epidemic-level proportions. In this action plan, DPA outlines a robust response focused on effective treatment, harm reduction, prevention… Read More
Harm reduction is a public health philosophy and intervention that seeks to reduce the harms associated with drug use and ineffective drug policies.
This issue brief explains New York's new 911 Good Samaritan Law that went into effect on September 18, 2011. Enclosed is background information about overdose deaths in New York, details about the new law which seeks to… Read More
Carl Hart, Associate Professor of Psychiatry and Psychology at Columbia University, offers a provocative, evidence-based view of addiction and discusses how it should impact drug policy.
DPA advocates for sharing reliable, accurate information about commonly used drugs so we can promote public health and reduce the harms around drug use. This booklet, produced by our New Mexico office, is designed to… Read More
The U.S. Food and Drug Administration (FDA) has approved three medications for use in treating opioid dependence: methadone, buprenorphine, and naltrexone. Extended release naltrexone, brand name Vivitrol®, is a… Read More